Changchun Hi-Tech announced that recently, the subsidiary Jinsai Pharmaceutical received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration. The application for registration of clinical trials for domestic production of GenSci 155 injection was approved and agreed to conduct clinical trials. The indications are to prevent bronchopulmonary dysplasia in premature infants and treat primary insulin-like growth factor-1 deficiency.

Changchun Hi-Tech announced that recently, the subsidiary Jinsai Pharmaceutical received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration. The application for registration of clinical trials for domestic production of GenSci 155 injection was approved and agreed to conduct clinical trials. The indications are to prevent bronchopulmonary dysplasia in premature infants and treat primary insulin-like growth factor-1 deficiency.